Lieff Cabraser Announces Settlement of Lovenox/Enoxaparin Drug Antitrust Class Action with Momenta and Sandoz
$120 million aggregate settlement will benefit hospitals, insurers and companies that pay for their employees’ healthcare costs, and uninsured people affected by the pharma companies’ alleged anticompetitive conduct Lieff Cabraser is proud to announce that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have agreed to settlements totaling $120 million in the antitrust class action about enoxaparin,